Biofrontera's Ameluz Gains FDA Approval for Expanded Use
Biofrontera Receives FDA Approval for Ameluz Expansion
Recently, Biofrontera Inc. announced significant news regarding its flagship product, Ameluz (aminolevulinic acid HCl) topical gel. The U.S. Food and Drug Administration (FDA) has officially approved a supplemental New Drug Application (sNDA) allowing the use of up to three tubes of Ameluz in a single photodynamic therapy (PDT) treatment for actinic keratosis (AK) on the face and scalp. This momentous approval is expected to enhance the standard of care for patients dealing with this common skin condition.
Wider Treatment Options for Actinic Keratosis
With this new approval, healthcare professionals now have the flexibility to treat larger fields effectively. The use of three tubes of Ameluz per session ensures that dermatologists can address greater or multiple treatment areas at once. This change not only benefits patients but also makes procedures more convenient for healthcare practitioners who perform PDT.
Implications of the Approval
Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc., expressed his enthusiasm about the FDA's decision. He stated, “We are thrilled with the FDA's decision to approve the use of up to three tubes of Ameluz per treatment. Our next steps involve working with Medicare and private payers to secure reimbursement for this expanded usage.”
Clinical Studies Supporting the Approval
The sNDA submitted by Biofrontera was supported by two pivotal Phase I safety studies, involving 116 participants in total. These studies demonstrated that the blood concentrations of the active component and its metabolite remained significantly below levels associated with side effects. The adverse events observed were comparable to those when only one tube of Ameluz was administered, establishing the treatment’s safety and efficacy.
Understanding Actinic Keratosis
Actinic keratosis represents the most prevalent pre-cancerous skin lesion resulting from long-term sun exposure. If neglected, these lesions can progress into the more serious squamous cell carcinoma. Regions most affected typically include sun-exposed skin areas such as the face, bald scalp, arms, and the backs of hands. A staggering estimate reveals that around 58 million Americans were afflicted by AK in recent years, with 13 million treatments performed annually.
The Role of Ameluz in Treatment
Ameluz is recognized as the sole PDT photosensitizer approved by the FDA that can be utilized for both lesion-directed and field-directed treatments of AK. Dr. Jonathan Weiss, an investigator and a co-managing partner at Georgia Dermatology Partners, has relied on Ameluz for over seven years for AK management due to its proven efficacy and safety. He remarked, “With the newer approval, I am eager to utilize up to three tubes for patients who require this level of treatment.”
About Biofrontera Inc.
Biofrontera Inc. is dedicated to advancing dermatological care. This U.S.-based biopharmaceutical company is focused on the development and commercialization of innovative therapies, particularly aimed at treating skin conditions through PDT. The company’s flagship product, Ameluz, is administered alongside the RhodoLED lamp series, specifically designed for effective PDT of AK and related skin disorders. They are also actively conducting clinical trials to explore broader applications, including treatment for non-melanoma skin cancers and severe acne.
Frequently Asked Questions
What is Ameluz approved for?
Ameluz is FDA-approved for the treatment of actinic keratosis (AK) using photodynamic therapy (PDT).
How many tubes of Ameluz can be used now?
With the latest FDA approval, healthcare providers can now use up to three tubes of Ameluz in a single treatment.
What does this approval mean for patients?
This approval enables doctors to treat larger areas affected by AK, thus providing more comprehensive care options for patients.
Has Ameluz been tested for safety?
Yes, the sNDA was supported by Phase I safety studies that demonstrated the treatment's safety and showed minimal side effects.
What is the significance of treating AK?
Treating AK is crucial because untreated lesions can lead to squamous cell carcinoma, making effective management vital.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Compulink Enhances IT Solutions for NYC Agencies Through Contract Growth
- Katie Jane Hughes Teams Up with Cosmetica for New Launch
- Transforming Onboarding: TradePMR's Advancements for Advisors
- AI Platform Alliance Launches Innovative Marketplace for Members
- Airheads Unveils Unique Cherry Scented Spray for Halloween Fun
- Brand Engagement Network Adjusts Stock Issuance Terms for Growth
- eXp World Holdings' $34M Settlement: What It Means Moving Forward
- Oslo Stock Index Declines Amid Mixed Sector Performance
- Innovative Digital Support for Caregivers of Alzheimer’s Patients
- BSR REIT Sets Date for Q3 2024 Financial Result Release
Recent Articles
- DraftKings Inc. Shares Surge with New Price Target of $50
- Analysts Revise Domino's Price Target Amid Sales Concerns
- BofA Downgrades Comerica, Evaluating Impact of Rate Cuts
- Darling Ingredients Faces Price Target Adjustment Amid Challenges
- Orbit International Corp. Returns to Trading on OTC Pink Market
- Tyra Biosciences’ Positive Trial Outlook Boosts Stock Ratings
- Galecto Shifts Strategic Focus to Oncology with New Acquisition
- Telos Corporation Expands TSA PreCheck Locations for Ease
- Domino's Pizza Adjusts Price Target Amid Sales Projections
- Pandora's New Share Buyback Programme and Capital Strategy
- China's Economic Revival: Anticipated Fiscal Stimulus Actions
- Prenetics Reports Impressive H1 2024 Results with Growth Outlook
- GRI Bio Showcases Breakthrough Research on Lung Fibrosis
- LOBO EV Technologies Projects Significant Revenue Growth for 2024
- OMNIQ and NEC Partner to Revolutionize Public Safety Solutions
- Barfresh Launches New Juice Freeze Pops Amid Record Revenue
- Inspired Entertainment Reveals Exciting Innovations at G2E 2024
- Impact BioMedical's Successful IPO Marks New Growth Phase
- Perfect Moment Unveils Exciting New Ski Collection for 2024
- DEEP GREEN Waste & Recycling Reports Impressive Revenue Growth
- Yoshinoya America Welcomes Glenn Lunde as New CEO
- AmpliTech Group Celebrates Patent Allowance in 5G and Quantum Tech
- Anixa Biosciences Welcomes Suyasha Gupta as Clinical Leader
- Walgreens Welcomes Jason Stenta as New Chief Commercial Officer
- Consumer Portfolio Services Innovates Loan Processing with AI
- Nissan Partners with ChargeScape to Enhance EV Charging Savings
- Examining Schouw & Co.'s Share Buy-Back Program Insights
- Cheniere Energy Plans Earnings Release for Q3 2024 Results
- Holiday Inn Express & Suites Cincinnati Riverfront's New Look
- GlobalFoundries to Host Conference Call for Q3 2024 Results
- Fisker's Financial Troubles Deepen Amid SEC Scrutiny
- Amkor Technology's Upcoming Financial Report and Insights
- Harold Beck & Sons Inc. Appoints William T. Fejes Jr. as CEO
- Rigetti's Vision for Quantum Computing and National Security
- Spark and Glow Plug Market Growth Insights for 2024-2034
- Inozyme Pharma Welcomes Erik Harris to Board for Growth Strategy
- RXO Announces Upcoming Earnings Call - Join the Discussion
- Discovering Agile Market Insights with Rival Technologies
- Territorial Bancorp Advocates for Hope Bancorp Merger Benefits
- MariMed Set to Reveal Third Quarter Earnings Soon
- Confluent, Inc. to Share Q3 2024 Financial Insights Soon
- Velan Inc. Faces Labor Strike at Williston Plant Amid Talks
- Highwire Welcomes Katherine Zackel as Crisis Lead Expert
- ESAB Corporation Plans Earnings Call for Q3 2024 Results
- Creator Influence Drives Increased Holiday Spending and Trust
- Understanding Learning Technologies Group: Recent Developments
- AnalytixInsight Shares Key Developments and Future Strategies
- Global Crossing Airlines Welcomes Laurie Villa as CPO
- Honoring Heroes: 9/11 Memorials and Service Events Across America
- China's Shift to Local AI Chips Poses Challenges for Nvidia